Zevra therapeutics reports corporate updates and third quarter 2023 financial results

Arimoclomol nda resubmission remains on track for end of year filing proposed acquisition of acer therapeutics on track to close q4 2023 and will diversify zevra's revenue with fda-approved olpruva ® for urea cycle disorders (ucds) net revenue of $2.9m for q3 2023 ended q3 2023 with $83. 4m in cash, cash equivalents, and investments, supporting our forecasted cash runway into 2026 conference call and live audio webcast scheduled for today, nov 7, 2023, 8:00 a.m.
ZVRA Ratings Summary
ZVRA Quant Ranking